10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELEVANCE HEALTH, INC. | |||
Ticker: ELV Fiscal Year: 2017 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 21, 2018) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Operating activities | |||
| Net income | $ 3,842,800 | 2,469,800 | 2,560,000 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Net realized gains on financial instruments | (144,800) | (4,900) | (157,500) |
| Other-than-temporary impairment losses recognized in income | 33,100 | 115,400 | 83,400 |
| Loss (gain) on extinguishment of debt | 282,400 | 0 | (9,300) |
| Loss on disposal of assets | 13,000 | 4,500 | 16,000 |
| Deferred income taxes | (1,272,100) | 126,900 | (65,900) |
| Amortization, net of accretion | 779,700 | 807,800 | 802,100 |
| Depreciation expense | 110,700 | 104,000 | 105,800 |
| Impairment of property and equipment | 2,500 | 44,800 | 1,800 |
| Share-based compensation | 169,600 | 164,600 | 148,200 |
| Excess tax benefits from share-based compensation | 0 | (53,500) | (95,800) |
| Changes in operating assets and liabilities: | |||
| Receivables, net | (22,200) | (1,380,500) | (42,900) |
| Other invested assets | (35,500) | (19,400) | 5,900 |
| Other assets | (629,000) | (127,700) | 33,800 |
| Policy liabilities | 731,600 | 321,700 | 193,000 |
| Unearned income | (120,100) | (173,600) | 33,900 |
| Accounts payable and accrued expenses | 921,800 | 182,300 | (123,400) |
| Other liabilities | (120,200) | 605,700 | 686,400 |
| Income taxes | (193,900) | 178,800 | 41,500 |
| Other, net | (164,600) | (96,500) | (5,100) |
| Net cash provided by operating activities | 4,184,800 | 3,270,200 | 4,211,900 |
| Investing activities | |||
| Purchases of fixed maturity securities | (9,794,600) | (10,157,700) | (9,792,000) |
| Proceeds from fixed maturity securities: | |||
| Sales | 7,931,700 | 8,636,000 | 8,909,200 |
| Maturities, calls and redemptions | 1,847,600 | 1,418,600 | 1,313,600 |
| Purchases of equity securities | (5,416,300) | (1,476,300) | (1,561,400) |
| Proceeds from sales of equity securities | 3,462,500 | 1,592,800 | 1,471,100 |
| Purchases of other invested assets | (1,163,800) | (433,100) | (505,800) |
| Proceeds from sales of other invested assets | 219,000 | 304,900 | 85,900 |
| Changes in collateral and settlement of non-hedging derivatives | 64,900 | (34,500) | (36,500) |
| Changes in securities lending collateral | 624,500 | 222,000 | 214,400 |
| Purchases of subsidiaries, net of cash acquired | (2,079,600) | 0 | (638,900) |
| Purchases of property and equipment | (799,500) | (583,600) | (638,200) |
| Proceeds from sales of property and equipment | 9,300 | 0 | 35,300 |
| Other, net | 11,900 | (3,000) | (8,200) |
| Net cash (used in) provided by investing activities | (5,082,400) | (513,900) | (1,151,500) |
| Financing activities | |||
| Net proceeds from (repayments of) commercial paper borrowings | 174,600 | (53,200) | 682,200 |
| Proceeds from long-term borrowings | 5,457,800 | 0 | 1,226,500 |
| Repayments of long-term borrowings | (2,815,100) | 0 | (2,697,200) |
| Proceeds from short-term borrowings | 5,835,000 | 2,400,000 | 2,760,000 |
| Repayments of short-term borrowings | (5,000,000) | (2,500,000) | (2,620,000) |
| Changes in securities lending payable | (624,500) | (222,000) | (214,400) |
| Changes in bank overdrafts | 71,000 | 513,800 | (243,800) |
| Premiums paid on equity call options | 0 | 0 | (16,700) |
| Proceeds from sale of put options | 900 | 0 | 16,600 |
| Repurchase and retirement of common stock | (1,997,700) | 0 | (1,515,800) |
| Change in collateral and settlements of debt-related derivatives | (149,000) | (360,400) | 0 |
| Cash dividends | (704,900) | (684,000) | (656,600) |
| Proceeds from issuance of common stock under employee stock plans | 225,300 | 119,400 | 186,000 |
| Taxes paid through withholding of common stock under employee stock plans | (46,500) | (65,700) | (95,900) |
| Excess tax benefits from share-based compensation | 0 | 53,500 | 95,800 |
| Net cash provided by (used in) financing activities | 426,900 | (798,600) | (3,093,300) |
| Effect of foreign exchange rates on cash and cash equivalents | 4,300 | 4,100 | (5,300) |
| Change in cash and cash equivalents | (466,400) | 1,961,800 | (38,200) |
| Cash and cash equivalents at beginning of year | 4,075,300 | 2,113,500 | |
| Cash and cash equivalents at end of year | 3,608,900 | 4,075,300 | 2,113,500 |
| External Links | |
| ELEVANCE HEALTH, INC. (ELV) Fiscal Year 2017 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |